PUBLISHER: DelveInsight | PRODUCT CODE: 1226658
PUBLISHER: DelveInsight | PRODUCT CODE: 1226658
"BT-11 Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about BT-11 for Ulcerative Colitis (UC) in the seven major markets. A detailed picture of the BT-11 for ulcerative colitis in the 7MM, i.e., the United States, EU4 (Germany, France, Italy and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the BT-11 for ulcerative colitis. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the BT-11 market forecast analysis for ulcerative colitis in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in ulcerative colitis.
BT-11 (omilancor) is Landos Biopharma's investigational new drug which is administered orally. It is first-in-class, a gut-restricted small molecule that targets the lanthionine synthetase c-like 2 (LANCL2) pathway that impacts the gastrointestinal tract. LANCL2 plays a vital role in the immunoregulatory process. By activating the LANCL2 pathway and modulating the interactions between immunological and metabolic signals in immune cells, BT-11 creates a favorable regulatory microenvironment in the gut, decreasing the production of key inflammatory mediators and increasing anti-inflammatory markers in regulatory T-cells (Treg) within the site of inflammation.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
BT-11 Analytical Perspective by DelveInsight
This report provides a detailed market assessment of BT-11 for ulcerative colitis in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2025 to 2032.
The report provides the clinical trials information of BT-11 for ulcerative colitis covering trial interventions, trial conditions, trial status, start and completion dates.
Key Questions